Loading stock data…
Amgen Inc. (AMGN)
$360.10+1.77 (+0.49%)
Market OpenUpdated 3:10 PM EDT
Amgen Inc.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Amgen Inc. in the Healthcare sector is trading at $360.30 with a market capitalization of $181.4B. Wall Street consensus targets $352.77 (30 analysts), implying a -2.1% move over the next 12 months. The stock is currently 8% below its 52-week high of $391.29, remaining 9.1% above its 200-day moving average. On fundamentals, Piotroski 7/9 indicates strong financial quality, Altman Z in the distress zone. The Whystock Score of 85/100 reflects bullish alignment across trend, valuation and analyst targets.
Ecosystem Influences
Sell-side consensus broadly in line with current price
Long-term trend bullish (price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Quarterly Financials
| Metric (USD) | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 |
|---|---|---|---|---|---|
| Total Revenue | $8.62B↓ | $9.87B↑ | $9.56B↑ | $9.18B↑ | $8.15B |
| Gross Profit | $5.87B↓ | $6.89B↑ | $6.47B↑ | $6.17B↑ | $5.18B |
| Operating Income | $2.67B↓ | $2.72B↑ | $2.53B↓ | $2.66B↑ | $1.18B |
| Net Income | $1.82B↑ | $1.33B↓ | $3.22B↑ | $1.43B↓ | $1.73B |
Peer Comparison
JNJUNHPFE
Fundamentals
Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel for the treatment of rheumatoid arthritis, plaque psoriasis, and psoriatic arthritis; Otezla for the treatment of...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$181.37B
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
23.37
Beta
Defensive asset. Lower volatility than the S&P 500.
0.43
Div Yield
Strong income play. Yield provides a meaningful total return floor.
2.02%
ROE
Elite ROE. Management converts capital into profit efficiently.
84.87%
Volume
Today's trading volume
1.35M
Recent News
BofA, Jefferies Start Quantinuum With Buy Ratings On 'Full-Stack' Platform
Jefferies initiated coverage of Quantinuum stock with a buy rating, touting the company's broad hardware and software platform.
Ipsen to Buy Kartos Therapeutics for Up to $1.75 Billion
The deal adds navtemadlin—a drug candidate for a rare blood cancer in late-stage clinical trials—to Ipsen’s oncology pipeline.
Alphabet Is Joining the Dow Jones Industrial Average. 3 Surprising Reasons Why SpaceX Could Be Next.
With just 30 components, the Dow's exclusivity is built on industry leadership, which SpaceX has in spades.
European Regulator Calls for Amgen’s Tavneos to Have Authorization Revoked
The committee is recommending that no new patients start treatment with Tavneos and that existing patients be switched to suitable alternatives.
Amgen's Tavneos Faces EU Revocation After CHMP Review
The European Medicines Agency said Friday that its Committee for Medicinal Products for Human Use (C